Frank Vargo was named Chief Financial Officer of Emergent BioSolutions Inc., succeeding Richard Lindahl. As of November 6, 2026, Emergent BioSolutions Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 5, 2026 to October 16, 2026, naming 1 appointment and 1 departure (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Emergent BioSolutions Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Emergent BioSolutions Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-05 to 2026-10-16. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Emergent BioSolutions Inc. files it.
Layoffs on record: about 93 jobs, latest 2026-08-05 (layoff filings and notices).
Also on the record for Emergent BioSolutions Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by American Century Investment Management, Inc. | 5.4% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.92% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 9% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.04% of the class | 5%+ stakes | Source |
| April 9, 2026 | Stake report, Schedule 13G, by Dimensional Fund Advisors LP | 5.3% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 6.76% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 7.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Emergent BioSolutions Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Emergent BioSolutions Inc. and the records around it.
Emergent BioSolutions Inc. elsewhere on the record
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- American Century ETF Trust also filed stake reports on 83 other companies: Visteon Corporation (Oct 2026), MarineMax, Inc. (Sep 2026), AdvanSix Inc. (Aug 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
- Dimensional Fund Advisors LP also filed stake reports on 366 other companies: Acadia Healthcare Co Inc (Oct 2026), ADT Inc (Oct 2026), AGCO Corp (Oct 2026)
Watch Emergent BioSolutions Inc.
Get an email when Emergent BioSolutions Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Emergent BioSolutions Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Emergent BioSolutions Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Emergent BioSolutions Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Out | Chief Financial Officer | 2026-12-31 | 8-K, 2026-10-16 | |
| 2026-10-16 | In | Chief Financial Officer | 8-K, 2026-10-16 | ||
| 2026-08-05 | Reported | not named in the filing | 8-K, 2026-08-05 |
Who leads Emergent BioSolutions Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Richard Lindahl, departure reported, effective 2026-12-31 (filed 2026-10-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Emergent BioSolutions Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Emergent BioSolutions Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Emergent BioSolutions Inc.Every change, in the filing's words
Departing: Richard Lindahl, Chief Financial Officer, effective 2026-12-31
On October 16, 2026, Emergent BioSolutions Inc. (the " Company ") announced that Richard Lindahl, the Company's Chief Financial Officer, will step down from his role as the Company's principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.
Appointed: Frank Vargo, Chief Financial Officer
The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company's Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.
- Prior to his retirement date, Mr. Lindahl will assist with the transition of his responsibilities, including the preparation and filing of the Company's Annual Report on Form 10-K for the year ending December 31, 2026.
- Mr. Lindahl's compensation as an advisor will be materially consistent with his current compensation.
- The Company thanks Mr. Lindahl for over eight years of dedicated service to the Company as its Chief Financial Officer.
- Frank Vargo, age 43, joined the Company in December 2019 as Director, Corporate FP&A and G&A. Mr. Vargo was named Vice President, Treasurer in November 2025.
- Prior to joining the Company, Mr. Vargo held roles of increasing responsibility in finance at Under Armor, Inc. and in the aerospace and defense industry.
- He holds an MBA from Texas A&M University and a bachelor's degree in engineering from the Georgia Institute of Technology.
- In connection with his promotion to Interim Chief Financial Officer, the Company's Board of Directors approved interim compensation pay of an additional $3,850 per pay period in addition to his current base salary of $328,000 for Mr. Vargo commencing January 1, 2027.
- Mr. Vargo's salary, bonus and equity awards will remain commensurate with his seniority and position before his appointment as Interim Chief Financial Officer and will be reviewed on the same cycle as those of the Company's other Emergent executive officers.
Reported
As such, Simon Lowry, the Company's Chief Medical Officer, Head of Research and Development will be leaving the Company effective August 19, 2026.
- In connection with the actions described above, on August 5, 2026 the Company also announced that it will eliminate the role of Chief Medical Officer, Head of Research and Development.
- The Company also announced that Stephanie Duatschek, Senior Vice President, Chief Global Strategy & Franchise Development Officer, will assume the role of Executive Vice President, Chief Growth Officer, with responsibility for the Company's strategic growth.
- Ms. Duatschek will continue reporting to the Company's Chief Executive Officer, Joseph Papa.
Tools for this story
Each opens in a new tab, filled in for Emergent BioSolutions Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.